IRIS
GERETTI, ANNA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.058
AS - Asia 4.459
EU - Europa 1.296
SA - Sud America 719
AF - Africa 77
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.616
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.932
SG - Singapore 1.877
HK - Hong Kong 851
CN - Cina 629
BR - Brasile 591
RU - Federazione Russa 420
VN - Vietnam 359
IT - Italia 292
JP - Giappone 278
BD - Bangladesh 243
FI - Finlandia 144
DE - Germania 77
FR - Francia 73
IN - India 64
MX - Messico 59
GB - Regno Unito 57
AR - Argentina 55
SE - Svezia 53
CA - Canada 46
UA - Ucraina 35
ID - Indonesia 30
AT - Austria 25
NL - Olanda 25
ZA - Sudafrica 25
IE - Irlanda 24
PL - Polonia 21
CO - Colombia 18
EC - Ecuador 17
PK - Pakistan 17
IR - Iran 16
ES - Italia 14
IQ - Iraq 14
PY - Paraguay 12
TR - Turchia 12
TN - Tunisia 10
AZ - Azerbaigian 9
CL - Cile 9
CH - Svizzera 8
EG - Egitto 8
CR - Costa Rica 7
KR - Corea 7
MA - Marocco 7
PE - Perù 7
JO - Giordania 6
SA - Arabia Saudita 6
AE - Emirati Arabi Uniti 5
KE - Kenya 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
UZ - Uzbekistan 5
VE - Venezuela 5
AU - Australia 4
ET - Etiopia 4
JM - Giamaica 4
LT - Lituania 4
MW - Malawi 4
MY - Malesia 4
OM - Oman 4
PH - Filippine 4
AL - Albania 3
CM - Camerun 3
DO - Repubblica Dominicana 3
HR - Croazia 3
NP - Nepal 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
BG - Bulgaria 2
DZ - Algeria 2
GH - Ghana 2
HU - Ungheria 2
IL - Israele 2
MT - Malta 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZW - Zimbabwe 2
AM - Armenia 1
BB - Barbados 1
BE - Belgio 1
BN - Brunei Darussalam 1
CG - Congo 1
CI - Costa d'Avorio 1
DK - Danimarca 1
GD - Grenada 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
NE - Niger 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
RS - Serbia 1
Totale 11.616
Salva come PNG Salva come JPEG
Città #
San Jose 960
Hong Kong 835
Singapore 650
Woodbridge 565
Houston 505
Wilmington 473
Council Bluffs 338
Tokyo 273
Ashburn 219
Beijing 162
Los Angeles 161
The Dalles 134
Ho Chi Minh City 120
Helsinki 114
Buffalo 109
Redondo Beach 99
Dallas 95
New York 88
Fairfield 76
Hanoi 70
Moscow 67
Chicago 61
Ann Arbor 56
Rome 52
Santa Clara 43
Mexico City 38
Seattle 35
São Paulo 33
North Bergen 32
Cambridge 31
Lauterbourg 30
Jacksonville 26
Dublin 22
Lappeenranta 22
Milan 22
Salt Lake City 21
Phoenix 18
Haiphong 17
Frankfurt am Main 15
Orem 15
Tehran 15
Johannesburg 14
Medford 14
Nuremberg 14
Rio de Janeiro 14
Chandler 13
Elk Grove Village 13
Kraków 13
Stockholm 13
Da Nang 12
London 12
Shaoxing 12
Amsterdam 11
Belo Horizonte 11
Dearborn 11
Atlanta 10
Bologna 10
Brasília 10
Denver 10
Naples 10
Changsha 9
Hefei 9
Philadelphia 9
Sterling 9
Vienna 9
Baku 8
Guarulhos 8
Quito 8
Ribeirão Preto 8
Salvador 8
Tampa 8
Zhengzhou 8
Biên Hòa 7
Brooklyn 7
Chennai 7
Dulles 7
Florence 7
Fortaleza 7
Lawrence 7
Menlo Park 7
Miami 7
Montreal 7
Munich 7
Zurich 7
Ajax 6
Baghdad 6
Bắc Ninh 6
Curitiba 6
Jakarta 6
Lima 6
Palermo 6
San José 6
Santiago 6
São Luís 6
Thái Bình 6
Toronto 6
Ankara 5
Bari 5
Bauru 5
Bogotá 5
Totale 7.221
Salva come PNG Salva come JPEG
Nome #
When and how to use maraviroc in HIV-infected patients 456
European guidelines on the clinical management of HIV-1 tropism testing 452
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: A multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing 404
Emerging patterns and implications of HIV-1 integrase inhibitor resistance 403
Optimal use of maraviroc in clinical practice 381
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis 269
Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants 259
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy 199
Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution 187
Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: A cross-sectional comparison with the general population 103
2024 European guidelines for the management of genital herpes 97
Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection 94
A contaminant-free assessment of Endogenous Retroviral RNA in human plasma 82
The evolving landscape of COVID-19: Factors associated with in-hospital COVID-19 related mortality during the 2023-2024 phase of JN.1 subvariant dominance 81
Plasma HIV-1 RNA detection below 50 copies/mL and risk of virologic rebound in patients receiving highly active antiretroviral therapy 80
A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action 79
A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance 76
Diagnostic performance evaluation of hepatitis B e antigen rapid diagnostic tests in Malawi 74
Research news in clinical context 72
British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015 68
Epidemiology of hepatitis B, C and D in Malawi: Systematic review 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1108 Medical Microbiology 11 Medical and Health Sciences 1103 Clinical Sciences 68
The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir 68
PATHWAYS UNDERLYING HDV PERSISTENCE ACT INDEPENDENTLY FROM THE EXTENT OF HBV RESEVOIR AND ARE SUSTAINED BY AN ABUNDANT PRODUCTION OF HBSAG DERIVED FROM INTEGRATED HBV-DNA P 214 66
Liver Fibrosis by Transient Elastography and Virologic Outcomes after Introduction of Tenofovir in Lamivudine-Experienced Adults with HIV and Hepatitis B Virus Coinfection in Ghana 65
Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: cross-sectional and longitudinal analyses 64
Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa 62
Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection 61
Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom 61
Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study 60
Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBVDNA in the setting of a limited or even absent HBV reservoir. 59
Safety and pharmacokinetic characterization of nacubactam, a novel ?-lactamase inhibitor, alone and in combination with meropenem, in healthy volunteers 56
A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi, suggests a historic mechanism of transmission 56
Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia 56
Age, time living with diagnosed HIV infection, and self-rated health 56
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-na{\"i}ve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): Study protocol for a randomised trial 56
Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey 54
Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis 54
Factors associated with persistence of plasma HIV-1 RNA during long-term continuously suppressive firstline antiretroviral therapy 53
HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir 53
Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy 53
Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression 52
HBsAg production from integrated HBV-DNA sustains HDV persistence in the setting of a limited or even absent HBV reservoir 52
Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA 52
HIV-1 subtypes: Epidemiology and significance for HIV management 51
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation 50
Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study). 49
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process 49
HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination 49
During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ 49
Primary herpes simplex virus type-2 infection as a cause of liver failure after liver transplantation 48
Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIVPositive adults receiving first-line antiretroviral therapy in Malawi 48
Attitudes of people in the UK with HIV who are antiretroviral (ART) na{\"i}ve to starting art at high CD4 counts for potential health benefit or to prevent HIV transmission 48
Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: Results from the cross-sectional ASTRA study 47
HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults 47
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients 46
Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data 46
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study 46
2014 European guideline on HIV testing 45
Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment 45
Occult hepatitis B virus coinfection in HIV-positive African migrants to the UK: A point prevalence study 45
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades 45
Hepatitis B virus infection in general practice across England: An analysis of the Royal College of General Practitioners Research and Surveillance Centre real-world database 45
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight) 45
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook 45
Causes, associated exposures, and outcomes of cirrhosis and hepatocellular carcinoma in Malawi: an observational cohort and case–control study 45
Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection 45
The gamma-glutamyl transpeptidase to platelet ratio (GPR) shows poor correlation with transient elastography measurements of liver fibrosis in HIV-positive patients with chronic hepatitis B in West Africa. Response to: {'}The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa{'} by Lemoine et al 44
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz 44
2017 European guidelines for the management of genital herpes 43
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment 43
Kinetics and Specificities of the T Helper?Cell Response to GP120 in the Asymptomatic Stage of HIV-1 Infection 42
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia 41
Cytotoxic T lymphocytes in AIDS pathogenesis: Lessons to be learned from the macaque model of simian immunodeficiency virus infection 41
Measuring Proviral HIV-1 DNA: Hurdles and Improvements to an Assay Monitoring Integration Events Utilising Human Alu Repeat Sequences 41
Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana 41
The impact of HIV drug resistance testing on changes to treatment 41
Antiretroviral resistance in clinical practice 40
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 40
An apparent paradox: Resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy 40
A virological perspective on resistance in highly treatment-experienced patients 40
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation 40
Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring 40
Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection 40
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions 40
British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 40
Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses 40
Development of a real-time multiplex RSV detection assay for difficult respiratory samples, using ultrasone waves and MNAzyme technology 40
Efficacy of once daily darunavir/ritonavir in PI-Na{\"i}ve, NNRTI-experienced patients in the ODIN trial 39
Patterns of HIV testing at a London teaching hospital between 2004 and 2007 39
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study 38
Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens 38
Antiretroviral resistance 38
Real-world prevalence of non-integrase INSTI resistance-associated mutations and virological outcomes in people who have recently acquired HIV-1 in the UK 38
Antibody screening tests variably overestimate the prevalence of hepatitis C virus infection among HIV-infected adults in Ghana 38
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis 38
Prevalence and characteristics of hepatitis B virus (HBV) coinfection among HIV-Positive women in South Africa and Botswana 38
Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal 38
IAPAC guidelines for optimizing the HIV care continuum for adults and adolescents 38
Low-level viraemia on HAART: Significance and management 37
Prospective pilot study on the relationship between seminal HIV-1 shedding and genital schistosomiasis in men receiving antiretroviral therapy along Lake Malawi 37
Totale 7.686
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.654
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.654
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 0 0 0 0 0 7
2021/202286 3 6 17 2 1 8 3 7 15 4 4 16
2022/202357 8 0 0 6 4 20 6 2 5 0 6 0
2023/202419 3 0 0 0 0 2 0 0 0 10 0 4
2024/20253.043 6 36 28 10 3 59 67 716 886 271 575 386
2025/20267.363 503 473 864 441 413 177 692 1.029 1.145 635 723 268
Totale 12.462